Rhythm Pharmaceuticals, Inc. RYTM Derivative assets
Derivative assets at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeAssets.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s derivative assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s derivative assets?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported derivative assets of $850K in Q1 2026.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s derivative assets?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s derivative assets has grown at a -4.1% compound annual growth rate (CAGR), from $1.34M to $1.18M.
- What does derivative assets mean?
- Fair value of derivative contracts (swaps, options, forwards, futures) in a net gain position — represents amounts owed to the firm by counterparties.